Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012

Assessing Prion Infectivity of Human Urine in Sporadic Creutzfeldt-Jakob Disease

Silvio Notari1, Liuting Qing1, Maurizio Pocchiari, Ayuna Dagdanova, Kristin Hatcher, Arend Dogterom, Jose F. Groisman, Ib Bo Lumholtz, Maria Puopolo, Corinne Lasmezas, Shu G. Chen, Qingzhong Kong, and Pierluigi GambettiComments to Author 
Author affiliations: Case Western Reserve University, Cleveland, Ohio, USA (S. Notari, L. Qing, A. Dagdanova, K. Hatcher, S.G. Chen, Q. Kong, P. Gambetti); Istituto Superiore di Sanità, Rome, Italy (M. Pocchiari, M. Puopolo); Ferring Pharmaceuticals, Hvidore, Denmark (A. Dogterom); Instituto Massone, Buenos Aires, Argentina (J.F. Groisman); BL Consult ApS, Copenhagen, Denmark (I.B. Lumholtz); The Scripps Research Institute, Jupiter, Florida, USA (C. Lasmezas)

Main Article

Table 2

Prion infectivity in microsomal fraction prepared from sCJDMM1 patient 4 and suspended in PBS or 100× concentrated and dialyzed urine*

Carrier Brain† dilution Incubation time, d, mean ± SEM Distribution Prion titer, ID50/g tissue†
PBS‡ 10−2 267 ± 14 5/5 7.2 × 106
100× concentrated and dialyzed normal human urine 10−1 262 ± 4 5/5 3.3 × 105
10−2 281 ± 7 5/5
10−3 377 ± 35 6/6
10−4 311, 335 2/4
10−5 >793 0/6
10−6 >702 0/6

*sCJD, sporadic Creutzfeldt-Jakob disease; PBS, phosphate-buffered saline; ID50, 50% infectious dose.
†Brain tissue equivalent.
‡Titer was the same as calculated in Table 1.

Main Article

1These authors contributed equally to this article.

Page created: December 22, 2011
Page updated: December 22, 2011
Page reviewed: December 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.